Live Breaking News & Updates on Press relations europe

Stay informed with the latest breaking news from Press relations europe on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Press relations europe and stay connected to the pulse of your community

Number of Shares and Voting Rights of ADOCIA as of February 28th, 2021

Number of Shares and Voting Rights of ADOCIA as of February 28th, 2021
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (
Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French
société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 ADOC) a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, releases its total number of outstanding shares as well as its voting rights as of February 28th, 2021.
Month
9 773 093
(1) The total number of theoretical voting rights (or "gross" voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.

Lacassagne , Midi-pyrees , France , French , James-salierno , Pramlintide-biochaperone , Raimund-gabriel , Ruth-group , Mc-services , Adocia-press-relations-europe , Regulatory-news , French-code-de-commerce

Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes

Adocia Initiates Phase 2 Clinical Trial for M1Pram in Patients with Type 1 Diabetes
1c
The study has been designed to define parameters for the upcoming Phase 3 trial planned for 2022
This study follows the promising results of the proof-of-concept Phase 1 trial announced on September 15, 2020
Regulatory News:
Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 ADOC), a clinical stage biopharmaceutical company focused on diabetes treatment and other metabolic diseases, announced today the initiation of a Phase 2 study in type 1 diabetes (T1D). The purpose of the study is to confirm and optimize the safety and efficacy of M1Pram in comparison with insulin lispro (Humalog

Germany , German , James-salierno , Olivier-soula , Eli-lilly , Pramlintide-biochaperone , Raimund-gabriel , Ruth-group , Mc-services , Adocia-press-relations-europe , Euronext-paris , Universal-registration-document

Number of Shares and Voting Rights of ADOCIA as of January 31, 2021

Number of Shares and Voting Rights of ADOCIA as of January 31, 2021
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (
Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA (Paris:ADOC), a French
société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Euronext Paris: FR0011184241 ADOC) a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, releases its total number of outstanding shares as well as its voting rights as of January 31, 2021.
Month
9 760 822
(1) The total number of theoretical voting rights (or "gross" voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.

Lacassagne , Midi-pyrees , France , French , Pramlintide-biochaperone-lispram , Biochaperone-aspram , James-salierno , Liraglutide-biochaperone , Raimund-gabriel , Mc-services , Ruth-group , Adocia-press-relations-europe

Number of Shares and Voting Rights of ADOCIA as of December 31, 2020

Number of Shares and Voting Rights of ADOCIA as of December 31, 2020
Regulatory News:
Pursuant to the provisions of article L. 233-8 II of the French Code de Commerce and article 223-16 of the French stock-market authorities (
Autorité des Marchés Financiers, or "AMF") charter ADOCIA SA, a French
société anonyme (corporation), 115, avenue Lacassagne, 69003 Lyon, (Paris:ADOC) (Euronext Paris: FR0011184241 ADOC) a clinical stage biopharmaceutical company focused on diabetes treatment with innovative formulations of approved proteins, releases its total number of outstanding shares as well as its voting rights as of December 31, 2020.
Month
9 763 237
(1) The total number of theoretical voting rights (or "gross" voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended.

Lacassagne , Midi-pyrees , France , Paris , France-general , French , Pramlintide-biochaperone-lispram , Biochaperone-aspram , James-salierno , Liraglutide-biochaperone , Raimund-gabriel , Mc-services

Adocia Announces Half Year Report on Adocia's Liquidity Agreement With Kepler Capital Markets

Adocia Announces Half Year Report on Adocia's Liquidity Agreement With Kepler Capital Markets
Regulatory News:
Under the liquidity agreement entrusted by Adocia (Paris:ADOC) to Kepler Capital Markets, the following resources were listed on the liquidity account
on
- Number of executions on sell side on semester: 355
- Traded volume on buy side on semester: 45,143 shares for 353,656.52
- Traded volume on sell side on semester: 47,151 shares for 374,968.20
As a reminder:
on June 30, 2020 on the liquidity account:
32,541 shares
15,026 shares
- 300,000.00
The liquidity agreement complies with AMF Decision n° 2018-01 dated 2nd July 2018, introducing liquidity agreements on equity securities as permitted market practice

Pramlintide-biochaperone-lispram , Biochaperone-aspram , James-salierno , Liraglutide-biochaperone , Raimund-gabriel , Mc-services , Ruth-group , Adocia-press-relations-europe , Regulatory-news , Kepler-capital-markets , Biochaperone-lispram , Reference-document